Interventional technology developer AngioDynamics reported an increase in revenues in the company's first quarter of fiscal 2023, although the firm's net loss grew. The company cited persistent inflation, as well as hospital staffing and procedural pressures, for the loss.
The company's net loss was $13 million for the quarter (end-August 31), compared with a net loss of $7 million in the same period a year ago. However, the company reported strong sales in the first quarter, with an increase of 5.9% to $81.5 million, compared with the same quarter the prior year.
In addition, AngioDynamics said its gross margin was negatively impacted by labor shortages and increased costs for labor, raw materials, and freight. Gross margin for the first quarter of fiscal 2023 was 51.9%, a decrease of 20 basis points compared with the first quarter of fiscal 2022.
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
